Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Hawley JE, Obradovic AZ, Dallos MC, Lim EA, Runcie K, Ager CR, McKiernan J, Anderson CB, Decastro GJ, Weintraub J, Virk R, Lowy I, Hu J, Chaimowitz MG, Guo XV, Zhang Y, Haffner MC, Worley J, Stein MN, Califano A, Drake CG. Hawley JE, et al. Among authors: drake cg. Cancer Cell. 2023 Nov 13;41(11):1972-1988.e5. doi: 10.1016/j.ccell.2023.10.006. Epub 2023 Nov 2. Cancer Cell. 2023. PMID: 37922910 Free article.
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. Mellman I, et al. Among authors: drake cg. Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Cancer Immunol Res. 2016. PMID: 27036972 Review.
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, Schaeffer EM, Drake CG, Feng F, Ross AE. Benzon B, et al. Among authors: drake cg. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):28-35. doi: 10.1038/pcan.2016.49. Epub 2016 Nov 1. Prostate Cancer Prostatic Dis. 2017. PMID: 27801901 Free PMC article.
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, Vogelzang NJ, Corman JM, Millard FE, Maher JC, Chang NN, DeVries T, Sheikh NA, Drake CG; STAND Investigators. Antonarakis ES, et al. Among authors: drake cg. Clin Cancer Res. 2017 May 15;23(10):2451-2459. doi: 10.1158/1078-0432.CCR-16-1780. Epub 2016 Nov 10. Clin Cancer Res. 2017. PMID: 27836866 Clinical Trial.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. McNeel DG, et al. Among authors: drake cg. J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016. J Immunother Cancer. 2016. PMID: 28031820 Free PMC article.
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA. Paller CJ, et al. Among authors: drake cg. Clin Cancer Res. 2018 Jan 15;24(2):306-315. doi: 10.1158/1078-0432.CCR-17-1100. Epub 2017 Nov 7. Clin Cancer Res. 2018. PMID: 29113986 Free PMC article. Clinical Trial.
412 results